Cargando…
Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma
BACKGROUND: To investigate on the expressions and the clinical significances of hepatocyte growth factor receptor (c-MET), phosphorylated c-MET (p-MET) and e2f-1 transcription factor in primary lesion of gastric adenocarcinoma (GC). METHOD: Tissue samples from the primary lesion of GC in patients wh...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895664/ https://www.ncbi.nlm.nih.gov/pubmed/24393368 http://dx.doi.org/10.1186/1756-0500-7-6 |
_version_ | 1782299992567840768 |
---|---|
author | Wu, Ju-gang Yu, Ji-wei Wu, Hong-biao Zheng, Lin-hai Ni, Xiao-chun Li, Xiao-qiang Du, Guang-ye Jiang, Bo-jian |
author_facet | Wu, Ju-gang Yu, Ji-wei Wu, Hong-biao Zheng, Lin-hai Ni, Xiao-chun Li, Xiao-qiang Du, Guang-ye Jiang, Bo-jian |
author_sort | Wu, Ju-gang |
collection | PubMed |
description | BACKGROUND: To investigate on the expressions and the clinical significances of hepatocyte growth factor receptor (c-MET), phosphorylated c-MET (p-MET) and e2f-1 transcription factor in primary lesion of gastric adenocarcinoma (GC). METHOD: Tissue samples from the primary lesion of GC in patients who accepted D(2)/D(3) radical gastrectomy with R(0)/R(1) resection were stained by immunohistochemistry of c-MET, p-MET, e2f-1 and Ki-67. The univariate and the multivariate analyses involving in clinicopathological parameters and prognostic factors were evaluated. RESULTS: The positivity rates for c-MET (66.12%, 80 cases/121 cases), p-MET (59.50%, 72 cases/121 cases), e2f-1 (38.84%, 47 cases/121 cases) and Ki-67 (72.73%, 88 cases/121 cases) in primary lesion of GC was significantly higher than that in non-cancerous tissue at 5 cm places far from the margin of primary lesion (P < 0.05, respectively). The deeper tumor invasion, the severer lymph node metastasis, the later stage of TNM and the higher expression of Ki-67 was respectively an independent risk factor for the higher expression of c-MET or p-MET, but the younger age and the shorter survival time was an independent risk factor for the higher expression of e2f-1 respectively. Survival analysis showed that the worse prognosis could be observed in the patients with the combination of both c-MET-positive and e2f-1-negative (P = 0.038) or both p-MET-positive and e2f-1-negative (P = 0.042). Cox analysis demonstrated that the severer lymphatic node metastasis and the higher positivity rate of c-MET, p-MET or e2f-1 were an independent prognosis factor respectively. The higher expression of e2f-1 was identified in patients with Stage I-II, which correlated with a shorter survival time. Survival analysis also revealed that the prognosis of patients with positive expression of e2f-1 at Stage I-II was significantly worse than that in patients with negative expression of e2f-1 (χ(2) = 13.437, P = 0.001). However, in the cases with Stage III-IV, no significant difference could be identified in the prognostic comparison between positive and negative expressions of e2f-1. CONCLUSIONS: The expression of c-MET or p-MET is an independent prognosis factor. It has been observed that the higher expression of e2f-1 occurred in the early stages while the lower expression of it in the later stages in GC. |
format | Online Article Text |
id | pubmed-3895664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38956642014-01-21 Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma Wu, Ju-gang Yu, Ji-wei Wu, Hong-biao Zheng, Lin-hai Ni, Xiao-chun Li, Xiao-qiang Du, Guang-ye Jiang, Bo-jian BMC Res Notes Research Article BACKGROUND: To investigate on the expressions and the clinical significances of hepatocyte growth factor receptor (c-MET), phosphorylated c-MET (p-MET) and e2f-1 transcription factor in primary lesion of gastric adenocarcinoma (GC). METHOD: Tissue samples from the primary lesion of GC in patients who accepted D(2)/D(3) radical gastrectomy with R(0)/R(1) resection were stained by immunohistochemistry of c-MET, p-MET, e2f-1 and Ki-67. The univariate and the multivariate analyses involving in clinicopathological parameters and prognostic factors were evaluated. RESULTS: The positivity rates for c-MET (66.12%, 80 cases/121 cases), p-MET (59.50%, 72 cases/121 cases), e2f-1 (38.84%, 47 cases/121 cases) and Ki-67 (72.73%, 88 cases/121 cases) in primary lesion of GC was significantly higher than that in non-cancerous tissue at 5 cm places far from the margin of primary lesion (P < 0.05, respectively). The deeper tumor invasion, the severer lymph node metastasis, the later stage of TNM and the higher expression of Ki-67 was respectively an independent risk factor for the higher expression of c-MET or p-MET, but the younger age and the shorter survival time was an independent risk factor for the higher expression of e2f-1 respectively. Survival analysis showed that the worse prognosis could be observed in the patients with the combination of both c-MET-positive and e2f-1-negative (P = 0.038) or both p-MET-positive and e2f-1-negative (P = 0.042). Cox analysis demonstrated that the severer lymphatic node metastasis and the higher positivity rate of c-MET, p-MET or e2f-1 were an independent prognosis factor respectively. The higher expression of e2f-1 was identified in patients with Stage I-II, which correlated with a shorter survival time. Survival analysis also revealed that the prognosis of patients with positive expression of e2f-1 at Stage I-II was significantly worse than that in patients with negative expression of e2f-1 (χ(2) = 13.437, P = 0.001). However, in the cases with Stage III-IV, no significant difference could be identified in the prognostic comparison between positive and negative expressions of e2f-1. CONCLUSIONS: The expression of c-MET or p-MET is an independent prognosis factor. It has been observed that the higher expression of e2f-1 occurred in the early stages while the lower expression of it in the later stages in GC. BioMed Central 2014-01-06 /pmc/articles/PMC3895664/ /pubmed/24393368 http://dx.doi.org/10.1186/1756-0500-7-6 Text en Copyright © 2014 Wu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wu, Ju-gang Yu, Ji-wei Wu, Hong-biao Zheng, Lin-hai Ni, Xiao-chun Li, Xiao-qiang Du, Guang-ye Jiang, Bo-jian Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma |
title | Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma |
title_full | Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma |
title_fullStr | Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma |
title_full_unstemmed | Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma |
title_short | Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma |
title_sort | expressions and clinical significances of c-met, p-met and e2f-1 in human gastric carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895664/ https://www.ncbi.nlm.nih.gov/pubmed/24393368 http://dx.doi.org/10.1186/1756-0500-7-6 |
work_keys_str_mv | AT wujugang expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma AT yujiwei expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma AT wuhongbiao expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma AT zhenglinhai expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma AT nixiaochun expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma AT lixiaoqiang expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma AT duguangye expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma AT jiangbojian expressionsandclinicalsignificancesofcmetpmetande2f1inhumangastriccarcinoma |